with relatively low risk, 2 and may help to identify the significant proportion of patients with septic shock and concomitant myocardial dysfunction or hypovolemia.
, and in eAppendix 5. In the Abstract, 2 sentences were removed and some values were rounded. The Trauma Screening Questionnaire row of Table 3 has an added footnote and the values for the Total Patients, PPV, and NPV columns should be 152, 44, and 89, respectively. In eAppendix 5, there is an added footnote and the values for sensitivity, specificity, LR+, and LR− columns in the Trauma Screening Questionnaire row should be 0.95 (0.90-0.97), 0.26 (0.22-0.30), 1.3 (1.2-1.4), and 0.20 (0.10-0.41), respectively. This article was corrected online. Table 2 , in the observed means row, the values shown in the Liraglutide columns (reported as −6.2, −4.8, −2.2) should have been reported as −5.9, −4.6, and −2.0, respectively; in addition, footnote "c" should have read "Number of participants not estimated." In Table 3 , in the "Increase" row in the "Change in net use of concomitant oral hypoglycemic agents" section, the first value in the Placebo column, reported as 7, should have been reported as 57. In panel "C" of eFigure 3 in the online Supplement, the value for placebo in the systolic blood pressure plot, reported as 1.2, should have been reported as 1.1. This article was corrected online. 
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